MHRA finds no link between GLP-1 receptor agonists and suicidal behaviour The regulator says it will continue to monitor the risk of severe psychiatric reactions and assess new data as they become available.…
Advantages and disadvantages of shorter antimicrobial courses An overview of the available evidence for shorter antimicrobial courses, including how this can be supported in practice and the potential positive impact on antimicrobial resistance.…
Government opens £400m investment programme to boost UK clinical trials The investment programme will increase the UK’s capacity for clinical trials and give researchers greater access to the latest equipment and technology, the government said.…
Psilocybin may be as effective as escitalopram in treating depression, study suggests A meta-analysis has found similar effectiveness of psilocybin compared with escitalopram in the treatment of depression, but the study does have limitations.…
Suicidal ideation more commonly reported as reaction to semaglutide than for all other drugs, study finds Researchers report that, for people taking antidepressants, suicidal ideation was reported 4.45 times as likely for semaglutide compared with adverse drug reactions from all other drugs.…
Largest ever trial of ketamine to treat alcohol abuse to launch across eight NHS sites The phase III clinical trial will explore the use of low-dose ketamine combined with psychological support as a therapy for people with alcohol use disorder.…
Is research really an exclusive activity or one we can all embrace? A pick of recent academic papers from Parastou Donyai, chief scientist at the Royal Pharmaceutical Society.…
One in ten people with chronic pain could experience opioid dependence, suggest study results The pooled prevalence of dependence and opioid use disorder was 9.3% across 148 studies, but the researchers say high heterogeneity means the results should be “interpreted with caution”.…
More than 20,000 inhalers returned since November 2023 through recycling pilot Exclusive: Since its launch in November 2023, 20,400 inhalers have been returned through the ‘Re-Hale’ scheme, which operates across 78 locations in East Kent.…
NSAID prescribing in high-risk groups is a major source of avoidable harm, study finds The study estimated that the practice could have caused more than 6,000 lost years of good health across England over a ten-year period.…
